NeuroDerm is developing transdermal delivery systems for the treatment of neurological diseases and related disorders. These transdermal delivery systems are based on unique proprietary formulations and a device that enables to maintain low but constant concentrations of the active drug in the blood. This will allow obtaining more efficacious pharmacological effect with reduced adverse effects. NeuroDerm strategy is to use compounds that are approved for human use, thereby shortening the process of the product approval by the health authorities. The development efforts are focused at developing formulations that will enhance transdermal penetration and a device that will be used for delivering a variety of drugs for prolonged periods. The first product to be developed is a transdermal delivery system of L-DOPA for the treatment of Parkinson's patients. Additional planed products are transdermal delivery systems for the treatment of Alzheimer's disease and xerostomia.